Dupixent Lawsuits

CTCL is a rare cancer that starts in the body’s immune system but shows up on the skin. It can look like eczema at first, with red, scaly, itchy patches. Over time, it can spread, forming thicker lesions, affecting the lymph nodes, and, in advanced cases, spreading to other organs. Because the early symptoms mimic common skin conditions, CTCL is often misdiagnosed or diagnosed late.

Studies published in 2024 and 2025 have shown that patients taking Dupixent^® are significantly more likely to develop CTCL compared to those who are not. Doctors believe Dupixent^® may unmask undiagnosed CTCL by suppressing eczema-like symptoms, making the cancer more visible only after it has progressed. Other research suggests the drug may play a role in accelerating the disease. The manufacturers of Dupixent^®, Sanofi and Regeneron, failed to communicate these risks to patients or prescribers.

If your child or family member taking Dupixent^® is not improving, or if their skin symptoms or rash seem to worsen, spread, or change in appearance, this can be a red flag. Other warning signs include unexplained itching, new nodules or lesions, swollen lymph nodes, or weight loss. Families should ask for a biopsy and further testing if symptoms do not improve.

A growing number of peer‑reviewed studies have looked closely at the connection between Dupixent^® and CTCL.

One 2024 study led by Hasan and colleagues found that patients with atopic dermatitis who were treated with Dupixent^® had more than a threefold higher risk of developing CTCL, twofold after adjusting for age, sex, and certain other factors.

Another 2024 analysis by Mandel et al. using TriNetX data reported a similarly elevated risk when comparing Dupixent^® users to non‑users.

In 2025, Ma and colleagues examined asthma patients who started Dupixent^® and found that the risk of CTCL was more than four times higher compared to those treated with other asthma drugs. The risk was even greater for certain T‑ and NK‑cell lymphomas after longer use.

Earlier reports, including a 2019 article in the Journal of the American Academy of Dermatology, documented cases where CTCL symptoms accelerated while patients were on Dupixent^®. Additional case reports continue to warn that the drug may unmask or worsen hidden lymphomas mistaken for eczema.

You may be eligible if you or a loved one were prescribed Dupixent^® and later diagnosed with CTCL. This includes parents or guardians filing on behalf of a minor child or families who lost a loved one. To support your claim, you will need to show medical records showing Dupixent^® use, the timing of symptoms and diagnosis, and whether cancer was discovered after treatment began. Our Dupixent^® Lawsuits attorneys can help you gather this information.

Yes. Dupixent^® has been FDA-approved for pediatric patients as young as six months old, and children make up a significant portion of those who have been prescribed it for moderate-to-severe eczema. If your child was prescribed Dupixent^® and later developed CTCL or another T-cell lymphoma, you may be able to bring a claim on their behalf. A parent or legal guardian typically brings the lawsuit for a minor child. The same evidence matters — medical records showing Dupixent^® use, the timing of the diagnosis, and the progression of symptoms. Contact our Mass Torts attorneys for a free consultation to discuss your child's situation.

Patients and families may be able to recover the costs of past and future medical treatment, lost income, and reduced earning capacity. Compensation may also be available for the pain, suffering, and emotional distress caused by the diagnosis. If your loved one died as a result of their CTCL, you may be able to seek damages for wrongful death, including loss of companionship and financial support.

Not always. Some cases resolve through negotiated settlements. But when drug manufacturers deny responsibility, litigation may be necessary. At Morris James, we are trial-ready and tested. If going to court is what it takes to protect our clients, we are prepared to stand before a jury.

Every state has its own statute of limitations, which sets a deadline for filing. In Delaware, these cases should typically be filed within two years of the injury or diagnosis but, because these deadlines vary, it is critical to speak with a lawyer as soon as possible to avoid losing your right to bring a claim.

At Morris James, there are no upfront costs. We represent Dupixent^® clients on a contingency fee basis, which means we only get paid if we recover compensation for you. Families can focus on medical care and healing while we handle the legal fight.